What is wrong with the current innovation system?
The existing innovation system in biological sciences encourages the private appropriation of critical enabling technologies through intellectual property rights, typically patents.
Increasingly, biological technologies are not self-contained, but instead are interdependent technologies requiring multiple key components to function to the point of delivery. Denial of access to any component prevents the use of the technology. With the massive increase in patenting of biological processes and materials, securing a pathway to delivery is virtually insurmountable by any but the most powerful corporations. For these entities, only the highest margin products merit attention, and thus they are not targeting products of interest to many smaller, less capital-rich markets.